Reading MYGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MYGN free→Reading MYGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MYGN free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, while risk is elevated and the sector backdrop is a headwind. Compared with sector peers, MYGN trades below typical levels. Peer multiples imply a price about 87% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $4.32. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.33 MYGN trades at 0× p/s, below its 4× p/s peer median. Our $35 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 87% below a flat-multiple fair value, below our forecast of about 2%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -0.01x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.01 → $-0.06 (-521.9% / 30d). 1 raised, 6 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d. 20% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$245.
How much price usually moves either way.
On a bad day, this stock has moved -$602.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,660.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Hitting the 68%-69% gross margin target shows good cost management. This affects profit outlook.
Confirms one read:Adjusted gross margin reported at 68% or higher in Q2.
Confirms the other:Adjusted gross margin reported below 68% in Q2.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MYGN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers As reported below in Item 5.07, Myriad Genetics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company's stockholders approved an amendment to the Company's Amended and Restated 2012 Employee Stock Purchase Plan (the "Purchase Plan"), to increase the number of shares authorized for issuance un…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Life Sciences Tools & Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MYGN Myriad Genetics, Inc. | Below typical Show detailsSector percentile: 14 of 100 | inexpensive | elevated |
TMO Thermo Fisher Scientific | Above typical Show detailsSector percentile: 95 of 100 | fair | moderate |
DHR Danaher Corporation | Above typical Show detailsSector percentile: 97 of 100 | fair | moderate |
A Agilent Technologies | Above typical Show detailsSector percentile: 92 of 100 | full | moderate |
WAT Waters Corporation | Above typical Show detailsSector percentile: 90 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to achieve a revenue range of $860 million to $880 million for the fiscal year 2026.
The company targets an adjusted gross margin percentage between 68% and 69% for the fiscal year 2026.
The company aims to achieve an adjusted EBITDA range of $37 million to $49 million for the fiscal year 2026.
Why it matters: Meeting the $37M-$49M adjusted EBITDA target shows good operations. This impacts future growth plans.
Confirms one read:Adjusted EBITDA reported within the $37M-$49M range in Q2.
Confirms the other:Adjusted EBITDA was below $37M in Q2.
Why it matters: Keeping or changing the $860M-$880M revenue guidance shows stable growth. This affects investor trust.
Confirms one read:Management says revenue guidance stays between $860M-$880M during the Q2 earnings call.
Confirms the other:Management cuts revenue guidance to below $860M during the Q2 earnings call.
Results of Operations and Financial Condition. On May 5, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended March 31, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…
Results of Operations and Financial Condition. On February 23, 2026 , Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, includ…
Results of Operations and Financial Condition. On January 12, 2026, Myriad Genetics, Inc. (the “Company”) issued a press release announcing its preliminary revenue for the quarter and full year ended December 31, 2025. The Company also introduced full year 2026 financial guidance. In addition, the Company is announcing certain preliminary volume information for the full year ended December 31, 2025. Specifically, the Company expects total test volumes in 2025 of approximately 1.5 million, a 1…
Results of Operations and Financial Condition. On November 3, 2025, Myriad Genetics, Inc. (“Myriad”) furnished a Current Report on Form 8-K that included a press release reporting financial results for the three months ended September 30, 2025 (the "Original Form 8-K"). Myriad is filing this Amendment No. 1 on Form 8-K/A to amend the Original Form 8-K solely to correct the amount shown for Cash, cash equivalents, and restricted cash at beginning of the period for the three months ended Septem…